For patients with eosinophilic granulomatosis with polyangiitis (EGPA), rituximab is not superior to the conventional ...

Rituximab does not outperform conventional therapy in inducing remission for eosinophilic granulomatosis with polyangiitis, a ...

Rituximab PK was assessed on days 1, 4, 15, 29, 31, 57 and 59 before rituximab and on days 4, 15, 31 and 59 following rituximab infusion, and at 1 or 3 months after treatment. Statistical methods ...

Rituximab is a chimeric human/mouse monoclonal antibody that is approved for the treatment of relapsed and refractory non-Hodgkin's lymphoma (NHL) and in combination with CHOP (cyclophosphamide ...

In conclusion, rituximab in association with subcutaneous 2-CdA is well tolerated, easily administered, and effective for symptomatic patients with newly diagnosed or pretreated WM. Our data confirm ...

Rituximab, a monoclonal antibody that targets the CD20 cell surface antigen, has clinical activity in patients with non-Hodgkin's lymphoma and other B-lymphocyte disorders when administered alone or ...

The committee accepted that the REACH trial demonstrated that the addition of rituximab to fludarabine and cyclophosphamide improved progression-free survival and complete response rates. The ...

Rituximab used off label appears tolerable and effective in a variety of autoimmune diseases. (Gottenberg JE et al. ; published online before print December 15, 2004.) ...

The manufacturer identified best supportive care as the comparator for rituximab monotherapy at second and subsequent relapse (the indication appraised in NICE's original technology appraisal guidance ...

Rituximab (Rituxan) may be a useful option for children with chronic steroid-dependent Henoch-Schonlein purpura, a small retrospective review suggested. Among eight children with this chronic ...

Correspondence Rituximab for Rheumatoid Arthritis Published October 28, 2004 N Engl J Med 2004;351: 1909 DOI: 10.1056/NEJM200410283511820 ...

Aug. 16 -- FRIDAY, Aug. 15 (HealthDay News) -- The drug rituximab may significantly reduce kidney damage in people with a common form of kidney disease called membranous nephropat ...